The EU CTR, or Clinical Trials Regulation, is a European Union law (Regulation No 536/2014) that governs how clinical trials are approved, conducted, and monitored across all EU member states. It replaced the older Clinical Trials Directive with a unified system designed to make it simpler to run multinational trials while strengthening transparency and participant safety. The regulation became fully applicable on January 31, 2022, and since January 31, 2025, it is the sole legal framework governing all clinical trials in the EU.
Why the EU Created a New System
Before the CTR, clinical trials in Europe were governed by the Clinical Trials Directive (2001/20/EC). Directives give EU countries a goal but let each one write its own national laws to get there. In practice, this meant a patchwork of different rules, timelines, and paperwork requirements across member states. A company wanting to test a drug in five countries had to submit five separate applications, deal with five different sets of procedures, and navigate inconsistent timelines. That fragmentation made the EU a less attractive place to run large-scale research.
The CTR is a regulation, not a directive. That distinction matters: a regulation applies directly and uniformly in every member state without needing to be translated into national law. The three core goals are to harmonize clinical trial rules across the EU, make it easier for both pharmaceutical companies and non-commercial sponsors to run multinational trials, and ultimately increase the number of studies conducted in Europe.
How the Single Portal Works
The centerpiece of the CTR is the Clinical Trials Information System, or CTIS. This is a single online portal where sponsors submit their trial applications, and where regulators across participating countries review them. Instead of filing separate applications in each country, a sponsor prepares one dossier and submits it through CTIS. Every national authority and ethics committee involved in the trial accesses the same system and follows the same procedures, regardless of which country they represent.
CTIS also includes a public-facing database. Healthcare professionals, patients, and the general public can search it for information about clinical trials happening across the EU. This level of built-in transparency was a deliberate design choice, not an afterthought.
Application and Assessment Timelines
One of the practical advantages of the CTR is a defined, predictable timeline for getting a trial approved. The entire evaluation process for an initial application, covering validation, assessment, and decision, generally takes up to 60 days.
The assessment phase itself can take up to 45 days. If regulators need more information from the sponsor, the clock pauses and extends by a maximum of 31 additional days. After the assessment wraps up, each participating country has up to five days to issue its decision on whether the trial can proceed in its territory. Compared to the old system, where timelines varied wildly from one country to the next, this is a significant improvement for planning purposes.
What the Application Covers
The CTR splits a clinical trial application into two parts. Part I covers the science: the trial design, the investigational drug, its expected benefits and risks, and the qualifications of the investigators. One country acts as the lead reviewer (called the Reporting Member State) and coordinates the assessment of Part I on behalf of all participating countries. Part II covers national and ethical requirements: informed consent procedures, participant recruitment, insurance arrangements, and site suitability. Each country reviews Part II independently for its own territory.
This split means that the core scientific evaluation happens once, avoiding duplication, while each country retains control over the ethical and local aspects that may differ based on national standards.
Transparency Requirements
The CTR sets a high bar for public disclosure. The CTIS public database makes trial information available to anyone, and the regulation treats transparency as a default rather than an opt-in feature.
There are defined exceptions. Information can be withheld to protect personal data, commercially confidential details (such as specific dosing information for early-stage trials where patent applications are pending), confidential communications between member states during assessment, or details that could interfere with a country’s ability to supervise a trial. Assessment reports, decision letters, and inspection reports are also excluded from public view. But the overall direction is clear: far more trial data is publicly accessible under the CTR than under the old directive.
Plain-Language Summaries for Patients
One of the more patient-focused features of the CTR is a requirement for sponsors to publish a summary of trial results written for a general audience. These aren’t the dense scientific reports filed with regulators. They must use simple, everyday language pitched at an average literacy level, with short sentences, bullet points, and no unexplained jargon. Technical terms, when unavoidable, must be defined in plain language first.
The summaries must present numbers as straightforward counts and percentages rather than statistical measures like relative risk or confidence intervals. Simple visual aids like infographics or basic graphs are encouraged, and each visual needs a text explanation that works even in black-and-white printing. The summaries must be provided in the local language of every EU country where the trial took place. They cover ten required elements, including the trial’s purpose, what treatments were tested, who participated, the main results, and safety findings.
Safety Reporting Under the CTR
When something goes wrong during a clinical trial, specifically when a participant experiences a serious and unexpected adverse reaction to the study drug, the sponsor must report it through a centralized system called EudraVigilance. These reports are known as SUSARs (suspected unexpected serious adverse reactions), and the CTR standardizes how they’re submitted across all member states.
Before sponsors can file these reports, they need to register with several EMA systems and designate a responsible person for safety reporting. They can either use a web-based tool provided by the EMA or send reports directly from their own safety database. The centralized approach means that a serious safety signal detected in one country becomes visible to regulators everywhere, rather than sitting in a national silo.
The Transition From the Old Directive
The CTR didn’t flip a switch overnight. The regulation allowed a three-year transition period running from January 31, 2022, to January 31, 2025. During that window, sponsors were responsible for migrating their existing trials from the old directive into CTIS. New trials submitted after the regulation took effect were automatically governed by the CTR.
As of January 31, 2025, the transition period ended. The old Clinical Trials Directive no longer applies, and every clinical trial in the EU, whether newly submitted or ongoing, falls exclusively under the CTR. Sponsors who failed to transition their trials into CTIS by that deadline could no longer legally continue those studies under the old framework.
Who the CTR Applies To
The regulation covers all clinical trials of medicinal products conducted in EU member states. The European Economic Area countries (Norway, Iceland, and Liechtenstein) also participate in the system through CTIS. Any sponsor, whether a large pharmaceutical company, a small biotech firm, or a university research group, follows the same procedures and uses the same portal. That uniformity was one of the regulation’s explicit goals: leveling the playing field so that non-commercial sponsors aren’t disadvantaged by the complexity of running trials across borders.